Pilot field study to assess efficacy of NexGard Combo®, a topical combination of esafoxolaner + eprinomectin + praziquantel, against natural Lynxacarus radovskyi infestation in cats.

This open-label, uncontrolled field study evaluated the efficacy and safety of a topical combination of esafoxolaner, eprinomectin, and praziquantel (at minimum doses of 1.4 mg/kg, 0.5 mg/kg, and 5 mg/kg, respectively) for the treatment of natural infestations with Lynxacarus radovskyi in 16 privately owned cats. Cats were recruited from three veterinary clinics based on inclusion criteria requiring confirmed L. radovskyi infestation and clinically healthy, with the exception of varying degrees of infestation-associated dermatological signs, including pruritus, alopecia, and scaling, were present at enrollment. All cats received a single topical treatment and served as their own controls; no negative untreated control group was included. Parasitological efficacy was assessed using semi-quantitative mite scoring, and clinical response was evaluated using lesion scores for pruritus, alopecia, and desquamation on Days 0, 15, and 30. The topical esafoxolaner treatment demonstrated 100% parasitological efficacy, with all cats free of detectable mites by Day 30 using semi-quantitative counting. Clinical signs improved markedly during the study period, and no adverse events were observed.